Aslan Pharmaceuticals Pte. Ltd. of Singapore announced a $12 million Series A funding, which it will use to in-license novel medicines. The company’s business model is to partner development-stage drugs that are 6-12 months from entering the clinic, perform Phase I and II studies in Asia to obtain Proof of Concept, and then out-license the compounds back to partners for global development. More details....